Institutional Investors, Endowments, Family Officers & Sovereign Funds Pour $1.46B to Invest in Biotech Fund

Apr 2, 2020 | Investor Watch, News

Institutional Investors, Endowments, Family Officers & Sovereign Funds Pour $1.46B to Invest in Biotech Fund

ARCH Venture Partners closed two new funds, ARCH Venture Fund X and ARCH Venture Fund X Overage, with a combined $1.46 billion to invest in transformative, early stage biotechnology companies. Limited partner investors include endowments, family offices, sovereign wealth funds and other institutional investors. The funds seek to invest in cutting-edge science, tools and talent to drive the discovery and development of medicines for a wide-range of diseases and conditions.

Large Pools of Capital

Growing pools of capital compete, scouring the globe in search of attractive early-stage life science investments. The funds are increasingly flexible, in that they will invest small amounts (in the hundreds of thousands) to hundreds of millions.


Early stage ARCH investments have included Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, Receptos, Agios Pharmaceuticals, Vir Biotechnology, Sage Therapeutics, bluebird bio, Codiak Biosciences, Denali Therapeutics, GRAIL, Karuna Therapeutics, Beam Therapeutics, Lyell Immunopharma, Sana Biotechnology, Brii Biosciences, Twist Bioscience, Aviron, Ikaria, Gossamer Bio, Fate Therapeutics, Array Biopharma, Adolor, Quanterix, 908 Devices, Unity Biotechnology, Hua Medicine, deCODE Genetics, Homology Medicines and others.


In their recent press release they touted the ARCH investments involved in the battle against COVID-19 including Vir Biotechnology, Alnylam Pharmaceuticals, VBI Vaccines, Brii Biosciences and Sana Biotechnology which are working on therapeutics; Quanterix is advancing technology that can help with clinical testing needs and support clinical trial continuity; Twist Bioscience is advancing genomic and gene engineering tools used in COVID-19 therapeutic and vaccine development; and Bellerophon’s inhaled nitric oxide (iNO) delivery system recently received emergency department expanded access approval from the U.S. Food and Drug Administration for treatment of COVID-19.

Pragmatic and Approachable

According to the investment firm’s press release, they will sit down with a scientist and a lab notebook, roll the sleeves up and work on translating science into great ventures.

Managing Directors

·       Robert Nelson

·       Keith Crandell

·       Kristina Burrow

·       Mark McDonnell

·       Steve Gillis

·       Paul Thurk

Source: ARCH


Pin It on Pinterest